|  |
| --- |
| **Table 3 The association between atrial fibrillation and the study outcomes in the sensitivity analyses** |
| **The study outcomes** | **adjusted hazard ratio** | **95% confidence interval** | **P** |
| **All-cause mortality at one year** |  |  |  |  |
|  **Model 1** | **2.416** | **1.204**  | **-4.845**  | **0.013** |
|  **Model 2** | **2.141** | **1.047**  | **-4.377**  | **0.037** |
|  **Model 3** | **2.533** | **1.304**  | **-4.917**  | **0.006** |
|  **Model 4** | **2.080** | **0.950**  | **-4.555**  | **0.067** |
|  **Model 5** | **2.158** | **1.012**  | **-4.605**  | **0.047** |
|  **Model 6** | **2.209** | **1.036**  | **-4.710**  | **0.040** |
| **Cardiac-related mortality** |  |  |  |  |
|  **Model 1** | **2.276** | **0.853**  | **-6.075**  | **0.101** |
|  **Model 2** | **2.176** | **0.801**  | **-5.913**  | **0.127** |
|  **Model 3** | **2.483** | **0.979**  | **-6.297**  | **0.055** |
|  **Model 4** | **2.022** | **0.708**  | **-5.778**  | **0.189** |
|  **Model 5** | **2.169** | **0.789**  | **-5.963**  | **0.133** |
|  **Model 6** | **2.169** | **0.792**  | **-5.938**  | **0.132** |
| **Major adverse cardiac events at one year** |  |  |  |  |
|  **Model 1** | **2.303** | **1.032**  | **-5.140**  | **0.042** |
|  **Model 2** | **1.869** | **0.795**  | **-4.393**  | **0.151** |
|  **Model 3** | **2.408** | **1.117**  | **-5.191**  | **0.025** |
|  **Model 4** | **1.682** | **0.699**  | **-4.048**  | **0.246** |
|  **Model 5** | **1.780** | **0.760**  | **-4.172**  | **0.184** |
|  **Model 6** | **1.757** | **0.753**  | **-4.099**  | **0.192** |
| **Model 1 adjusted for creatinine in addition to age, gender, heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** |
| **Model 2 adjusted for creatinine clearance in addition to heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** |
| **Model 3 adjusted for estimated glomerular filtration rate in addition to heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** |
| **Mode 4 additionally adjusted for body mass index on the top of the model 1.** |  |
| **Model 5 additionally adjusted for body mass index on the top of model 2.** |  |  |
| **Model 6 additionally adjusted for body mass index on the top of model 3.** |  |  |